This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harrison, E. F.
Right arrow Articles by Zygmunt, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harrison, E. F.
Right arrow Articles by Zygmunt, W. A.

 Previous Article  |  Next Article 

J Bacteriol. 1967 February; 93(2): 520-524
Copyright © 1967 American Society for Microbiology. All Rights Reserved.

Lysostaphin in Experimental Renal Infections

Edward F. Harrison and Walter A. Zygmunt

Department of Microbiology and Natural Products Research, Mead Johnson Research Center, Evansville, Indiana

ABSTRACT

By use of a renal staphylococcal infection model in mice, single intravenous doses of lysostaphin ranging from 1.56 to 50 mg/kg were effective in: (i) controlling the staphylococcal population of kidneys, (ii) reducing the mortality rate, and (iii) clearing high numbers of kidneys of infection. Semisynthetic penicillins and other antistaphylococcal antibiotics given in the same manner did not have significant activity. Only by the administration of a long-acting, depot form of penicillin (Bicillin) could results comparable to those seen with lysostaphin be obtained. The results of this study suggest that lysostaphin may be useful in staphylococcal septicemias in preventing the establishment of new foci of infection.

J Bacteriol. 1967 February; 93(2): 520-524
Copyright © 1967 American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Yang, X.-Y., Li, C.-R., Lou, R.-H., Wang, Y.-M., Zhang, W.-X., Chen, H.-Z., Huang, Q.-S., Han, Y.-X., Jiang, J.-D., You, X.-F. (2007). In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China. J Med Microbiol 56: 71-76 [Abstract] [Full Text]  
  • Kiri, N., Archer, G., Climo, M. W. (2002). Combinations of Lysostaphin with {beta}-Lactams Are Synergistic against Oxacillin-Resistant Staphylococcus epidermidis. Antimicrob. Agents Chemother. 46: 2017-2020 [Abstract] [Full Text]  
  • Climo, M. W., Ehlert, K., Archer, G. L. (2001). Mechanism and Suppression of Lysostaphin Resistance in Oxacillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 1431-1437 [Abstract] [Full Text]  
  • Patron, R. L., Climo, M. W., Goldstein, B. P., Archer, G. L. (1999). Lysostaphin Treatment of Experimental Aortic Valve Endocarditis Caused by a Staphylococcus aureus Isolate with Reduced Susceptibility to Vancomycin. Antimicrob. Agents Chemother. 43: 1754-1755 [Abstract] [Full Text]  
  • Climo, M. W., Patron, R. L., Goldstein, B. P., Archer, G. L. (1998). Lysostaphin Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Aortic Valve Endocarditis. Antimicrob. Agents Chemother. 42: 1355-1360 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»